Your Health, We Care
On March 19, 2024, Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration (FDA) had approved the supplemental New Drug Application (sNDA) for ponatinib (Iclusig, generic name: ponatinib) for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Takeda Pharmaceutical’s ponatinib (Iclusig, generic name: ponatinib) for the treatment of adult patients with chronic-phase chronic myeloid leukemia (CML) who are resistant or intolerant to prior therapies.
On December 14, 2012, the U.S. Food and Drug Administration (FDA) approved ponatinib (Iclusig) for the treatment of two rare types of leukemia.
Ponatinib is an oral targeted drug specifically indicated for the treatment of c···【more】
Release date：2026-01-20Recommended：99
Takeda Pharmaceutical Company Limited (Takeda) recently announced that the U.S. ···【more】
Release date：2026-01-20Recommended：113
Ponatinib, a third-generation BCR-ABL tyrosine kinase inhibitor (TKI), was devel···【more】
Release date：2026-01-20Recommended：108
On March 19, Takeda announced that the U.S. Food and Drug Administration (FDA) h···【more】
Release date：2026-01-20Recommended：138
Takeda Pharmaceutical Company Limited (Takeda) recently announced that the Phase···【more】
Release date：2026-01-20Recommended：149
